...
Announcement - Emerging Trends and Technologies Working Group Has Changed its Name! |
|---|
There’s been an exciting change in Working Groups recently… The Emerging Trends and Technologies Working Group has officially evolved into the Emerging Trends and Innovation Working Group! Why the change? Working Group Lead Mike Hamidi shares what brought about this change of name and scope: "The name change from Emerging Trends & Technologies to Emerging Trends & Innovation reflects a broader focus beyond technological enablement. This shift encompasses ongoing developments in areas such as AI/ML, digital health technologies and healthcare standards and aims to provide deeper insights into these and other evolving topics. This adjustment will preserve the emphasis on emerging trends while enhancing our commitment to delivering valuable industry insights and innovations.” We are equally excited to welcome Mark Bynens, the new Working Group Lead. He joins Mike Hamidi and Stuart Malcolm, expanding the team’s expertise and capacity. Mark Bynens brings a wealth of experience as Director and Scientific Computing Operations (SCO) Head within Statistics & Decision Sciences (SDS), Global Development at Johnson & Johnson. Mark leads initiatives in change management, project management, education, high-performance computing, and statistical research. Learn more about the Working Group Leads and their efforts here. Would you like to get involved in Working Groups? Check out the new Project Volunteer Board to view all opportunities. |
...
A new Data Transparency deliverable is out for public review! The Rare Disease/Small Population Data Sharing project has produced a new White paper; “Rare Disease Clinical Data Sharing” and are seeking your feedback. The purpose of this whitepaper is to review potential barriers to the sharing of rare disease data such as risk of re-identification and invasion of privacy (balanced against maintaining data utility) and understand if, and how, these barriers apply to controlled access data sharing under specific contextual assumptions. The development of strategies to enable rare disease data to be shared effectively and be reused is needed to advance research and clinical trial design where there is significant unmet need.. Email workinggroups@phuse.global by Monday 7th April to contribute your feedback! Find Out More: Advance Hub Rare Disease Project Page |
The SDTM ADaM Implementation FAQ project within the Optimizing the Use of Data Standards Working Group has published two new FAQs! They have answered a FAQ within Data Submission, the FAQ answered looks at the ‘Correct Implementation of the Define-XML Standard for Submission Purposes – ADaM and SDTM Variable Alignment’ and ‘Correct Implementation of the Define-XML Standard for Submission Purposes – Clarifications Needed’. You can view this question and see the FAQ's this project has answered so far here. Do you have a SDTM ADaM Implementation FAQ question? You can send your questions to the team by emailing workinggroups@phuse.global. |
...